ID

22302

Descrição

Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Subject Status / Response Assessment, 6 Month Post-Therapy Follow-up Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Link

https://clinicaltrials.gov/ct2/show/NCT00078572

Palavras-chave

Versões (1)
  1. 29/05/2017 29/05/2017 -
Transferido a

29 de maio de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY-NC 3.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

Inglês

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

1 Formulários  
Subject Status
Descrição

Subject Status

Alias
UMLS CUI-1
C2348568
UMLS CUI-2
C1522577
UMLS CUI-3
C0678222
Date of assessment
Descrição

Date of assessment

Tipo de dados

date

Alias
UMLS CUI [1]
C0011008
Is the subject alive?
Descrição

If NO, complete the END OF STUDY RECORD.

Tipo de dados

text

Alias
UMLS CUI [1,1]
C2584946
UMLS CUI [1,2]
C2348568
Has this subject started any anti-cancer therapy since the last contact?
Descrição

anti-cancer therapy

Tipo de dados

text

Alias
UMLS CUI [1]
C0920425
If YES, start date of anti-cancer therapy
Descrição

start date of anti-cancer therapy

Tipo de dados

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0920425
Therapy given
Descrição

Therapy given

Tipo de dados

text

Alias
UMLS CUI [1]
C0920425
Response Assessment
Descrição

Response Assessment

Alias
UMLS CUI-1
C0521982
UMLS CUI-2
C0220825
UMLS CUI-3
C0678222
Has disease progression previously been reported?
Descrição

If NO, complete the rest of this page.

Tipo de dados

text

Alias
UMLS CUI [1]
C0242656
Date of lesion evaluation
Descrição

lesion

Tipo de dados

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0221198
UMLS CUI [1,3]
C0220825
Response assessment, check one:
Descrição

Response assessment

Tipo de dados

text

Alias
UMLS CUI [1]
C0521982
If progressive disease is checked, indicate the primary method of evaluation.
Descrição

method

Tipo de dados

text

Alias
UMLS CUI [1,1]
C0871511
UMLS CUI [1,2]
C0221198
UMLS CUI [1,3]
C0220825
Date of symptomatic progression of cancer
Descrição

If Symptomatic progression of cancer is checked, complete details below

Tipo de dados

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C0178874
Specify symptoms
Descrição

Specify symptoms

Tipo de dados

text

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0178874
Voltar ao início da página

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Subject Status
C2348568 (UMLS CUI-1)
C1522577 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
Date of assessment
Item
Date of assessment
date
C0011008 (UMLS CUI [1])
Item
Is the subject alive?
text
C2584946 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Is the subject alive?
Code List
Is the subject alive?
CL Item
Yes (Y)
CL Item
No (N)
Item
Has this subject started any anti-cancer therapy since the last contact?
text
C0920425 (UMLS CUI [1])
Is the subject alive?
Code List
Has this subject started any anti-cancer therapy since the last contact?
CL Item
Yes (Y)
CL Item
No (N)
start date of anti-cancer therapy
Item
If YES, start date of anti-cancer therapy
date
C0808070 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
Therapy given
Item
Therapy given
text
C0920425 (UMLS CUI [1])
Item Group
Response Assessment
C0521982 (UMLS CUI-1)
C0220825 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
Item
Has disease progression previously been reported?
text
C0242656 (UMLS CUI [1])
Is the subject alive?
Code List
Has disease progression previously been reported?
CL Item
Yes (Y)
CL Item
No (N)
lesion
Item
Date of lesion evaluation
date
C0011008 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
Item
Response assessment, check one:
text
C0521982 (UMLS CUI [1])
Response assessment
Code List
Response assessment, check one:
CL Item
Complete response (CR)
CL Item
Partial response (PR)
CL Item
Stable disease (SD)
CL Item
Progressive disease (PD)
CL Item
Unknown (U)
Item
If progressive disease is checked, indicate the primary method of evaluation.
text
C0871511 (UMLS CUI [1,1])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
primary method of evaluation
Code List
If progressive disease is checked, indicate the primary method of evaluation.
CL Item
Progressive disease by lesion evaluation (PLE)
CL Item
Symptomatic progression of cancer (SPC)
Date of symptomatic progression of cancer
Item
Date of symptomatic progression of cancer
date
C0011008 (UMLS CUI [1,1])
C0178874 (UMLS CUI [1,2])
Specify symptoms
Item
Specify symptoms
text
C1457887 (UMLS CUI [1,1])
C0178874 (UMLS CUI [1,2])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial